1.17
-0.16(-12.03%)
Currency In USD
Address
37000 Grand River Avenue
Farmington Hills, MI 48335
United States of America
Phone
248 681 9815
Website
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
November 10, 2005
| Name | Title | Pay | Year Born |
| Mr. George Magrath M.B.A., M.D., M.S. | Chief Executive Officer & Director | 625,071 | 1984 |
| Dr. Jay S. Pepose M.D., Ph.D. | Chief Medical Advisor & Director | 392,000 | 1955 |
| Ms. Amy Zaremba Rabourn C.P.A., MAcc | Senior Vice President of Finance | 434,100 | 1981 |
| Mr. Bernhard Hoffmann M.B.A. | Senior Vice President of Corporate Development & Secretary | 434,100 | 1956 |
| Ms. Bindu Manne | Head of Market Development & Commercialization | 0 | N/A |
| Mr. Nirav Suresh Jhaveri C.F.A. | Chief Financial Officer | 0 | 1978 |
| Mr. Erik Sims | Director & Corporate Controller | 0 | N/A |
| Mr. Joseph K. Schachle MBA | Chief Operating Officer | 0 | 1965 |
| Dr. Ashwath Jayagopal Ph.D. | Chief Scientific & Development Officer | 0 | 1982 |
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.